Understanding how RUNX1 affects blood cell formation in Down syndrome
Function of RUNX1 in diverse Down syndrome tissues
This study is looking at how a specific protein called RUNX1 affects blood cell development in people with Down syndrome, and it will also test if certain drugs can help improve this process by adjusting RUNX1 levels.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado NIH-funded |
| Lab location | 1 site (Boulder, UNITED STATES) |
| Project ID | NIH-10099762 on NIH RePORTER |
What this research studies
This research investigates the role of RUNX1, a transcription factor located on chromosome 21, in the blood differentiation processes of individuals with Down syndrome. The study aims to determine how RUNX1's ability to bind DNA and influence RNA polymerase activity is altered in these individuals. Researchers will also explore the effects of drugs that modify RUNX1 function on cells with an extra chromosome 21. By normalizing RUNX1 levels in trisomy cell lines and differentiating induced pluripotent stem cells (iPSCs) into blood cells, the research seeks to clarify the impact of RUNX1 on blood cell formation in Down syndrome.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with Down syndrome, particularly those experiencing blood differentiation issues.
Not a fit: Patients without Down syndrome or those not experiencing blood-related complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and potential treatments for blood-related issues in individuals with Down syndrome.
How similar studies have performed: While the specific focus on RUNX1 in Down syndrome is novel, similar studies on transcription factors and blood differentiation have shown promising results.
Where this research is happening
Boulder, UNITED STATES
- University of Colorado — Boulder, United States (Active)
Researchers
- Principal investigator: Allen, Mary a — University of Colorado
- Study coordinator: Allen, Mary a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.